DK0758394T3 - Bifunktionelt protein, fremstilling og anvendelse - Google Patents
Bifunktionelt protein, fremstilling og anvendelseInfo
- Publication number
- DK0758394T3 DK0758394T3 DK95918576T DK95918576T DK0758394T3 DK 0758394 T3 DK0758394 T3 DK 0758394T3 DK 95918576 T DK95918576 T DK 95918576T DK 95918576 T DK95918576 T DK 95918576T DK 0758394 T3 DK0758394 T3 DK 0758394T3
- Authority
- DK
- Denmark
- Prior art keywords
- sub
- hinge region
- zeta
- bifunctional protein
- joined
- Prior art date
Links
- 230000001588 bifunctional effect Effects 0.000 title abstract 3
- 102000004169 proteins and genes Human genes 0.000 title abstract 3
- 108090000623 proteins and genes Proteins 0.000 title abstract 3
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 abstract 2
- 108010092262 T-Cell Antigen Receptors Proteins 0.000 abstract 2
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 230000001086 cytosolic effect Effects 0.000 abstract 1
- 231100000433 cytotoxic Toxicity 0.000 abstract 1
- 230000001472 cytotoxic effect Effects 0.000 abstract 1
- 210000004698 lymphocyte Anatomy 0.000 abstract 1
- 210000004881 tumor cell Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70517—CD8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP94810244 | 1994-05-02 | ||
PCT/EP1995/001494 WO1995030014A1 (fr) | 1994-05-02 | 1995-04-20 | Proteine a double fonction, sa preparation et son utilisation |
Publications (1)
Publication Number | Publication Date |
---|---|
DK0758394T3 true DK0758394T3 (da) | 2003-03-03 |
Family
ID=8218248
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK95918576T DK0758394T3 (da) | 1994-05-02 | 1995-04-20 | Bifunktionelt protein, fremstilling og anvendelse |
Country Status (18)
Country | Link |
---|---|
US (1) | US6984382B1 (fr) |
EP (1) | EP0758394B1 (fr) |
JP (1) | JP3742103B2 (fr) |
KR (1) | KR100373813B1 (fr) |
AT (1) | ATE228166T1 (fr) |
AU (1) | AU694222B2 (fr) |
CA (1) | CA2188422C (fr) |
DE (1) | DE69528894T2 (fr) |
DK (1) | DK0758394T3 (fr) |
ES (1) | ES2185705T3 (fr) |
FI (1) | FI119191B (fr) |
IL (1) | IL113530A0 (fr) |
NO (1) | NO316923B1 (fr) |
NZ (1) | NZ285395A (fr) |
PT (1) | PT758394E (fr) |
TW (1) | TW428026B (fr) |
WO (1) | WO1995030014A1 (fr) |
ZA (1) | ZA953440B (fr) |
Families Citing this family (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ285395A (en) | 1994-05-02 | 1998-10-28 | Novartis Ag | Chimeric antibody, cancer treatment |
EP0870040A2 (fr) * | 1995-12-29 | 1998-10-14 | Chiron Corporation | Ligands de ciblage de vehicules pour l'apport de genes |
AU4373197A (en) * | 1996-09-19 | 1998-04-14 | Diagnocure Inc. | Recombinant single chain antibodies directed against the gp54 cancer marker, composition comprising same and use thereof |
US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
DE10121113A1 (de) * | 2001-04-28 | 2002-10-31 | Gabriele Pecher | Genmodifizierte YT Zelllinie und ihre Verwendung |
DK2801583T3 (en) | 2004-07-10 | 2018-07-16 | Fox Chase Cancer Center | Genetically modified human natural killer cell lines |
US7994298B2 (en) | 2004-09-24 | 2011-08-09 | Trustees Of Dartmouth College | Chimeric NK receptor and methods for treating cancer |
PT2298815E (pt) | 2005-07-25 | 2015-07-16 | Emergent Product Dev Seattle | Moléculas de ligaçao especificas para cd37 e especificas para cd20 |
CA3149553C (fr) * | 2006-06-12 | 2023-11-21 | Aptevo Research And Development Llc | Proteines de liaison monocatenaires polyvalentes dotees d'une fonction d'effecteur |
WO2008045437A2 (fr) * | 2006-10-09 | 2008-04-17 | The General Hospital Corporation | RÉCEPTEURS CHIMÉRIQUES DES CELLULES T ET CELLULES T CIBLANT LE EGFRvIII SUR DES TUMEURS |
CA2719924C (fr) | 2008-04-11 | 2017-10-03 | Philip Tan | Produits d'immunotherapie de cd37 et combinaison avec un produit chimiotherapique bifonctionnel de celui-ci |
US9273283B2 (en) | 2009-10-29 | 2016-03-01 | The Trustees Of Dartmouth College | Method of producing T cell receptor-deficient T cells expressing a chimeric receptor |
US9181527B2 (en) | 2009-10-29 | 2015-11-10 | The Trustees Of Dartmouth College | T cell receptor-deficient T cell compositions |
ES2754394T3 (es) | 2010-09-08 | 2020-04-17 | Chemotherapeutisches Forschungsinstitut Georg Speyer Haus | Receptores de antígenos quiméricos con una región bisagra optimizada |
DK2649086T3 (en) | 2010-12-09 | 2017-09-18 | Univ Pennsylvania | USING CHEMICAL ANTIGEN RECEPTOR-MODIFIED T-CELLS TO TREAT CANCER |
WO2013033626A2 (fr) | 2011-08-31 | 2013-03-07 | Trustees Of Dartmouth College | Produits thérapeutiques ciblant un récepteur nkp30 |
ES2719495T3 (es) | 2012-05-07 | 2019-07-10 | Dartmouth College | Anticuerpo dirigido contra b7-h6, proteínas de fusión, y métodos de uso de los mismos |
RU2708032C2 (ru) | 2013-02-20 | 2019-12-03 | Новартис Аг | ЛЕЧЕНИЕ РАКА С ИСПОЛЬЗОВАНИЕМ ХИМЕРНОГО АНТИГЕНСПЕЦИФИЧЕСКОГО РЕЦЕПТОРА НА ОСНОВЕ ГУМАНИЗИРОВАННОГО АНТИТЕЛА ПРОТИВ EGFRvIII |
TW201446794A (zh) | 2013-02-20 | 2014-12-16 | Novartis Ag | 利用抗-cd123嵌合抗原受體工程化t細胞之初級人類白血病有效靶向 |
EP2970426B1 (fr) | 2013-03-15 | 2019-08-28 | Michael C. Milone | Ciblage de cellules cytotoxiques par des récepteurs chimériques pour une immunothérapie adoptive |
UY35468A (es) | 2013-03-16 | 2014-10-31 | Novartis Ag | Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19 |
US10640569B2 (en) | 2013-12-19 | 2020-05-05 | Novartis Ag | Human mesothelin chimeric antigen receptors and uses thereof |
EP3087101B1 (fr) | 2013-12-20 | 2024-06-05 | Novartis AG | Récepteur d'antigène chimérique régulable |
WO2015112626A1 (fr) | 2014-01-21 | 2015-07-30 | June Carl H | Capacité améliorée de présentation de l'antigène de lymphocytes t de récepteur d'antigène chimérique (car) par l'introduction conjointe de molécules de stimulation conjointe |
IL280215B (en) | 2014-04-07 | 2022-07-01 | Novartis Ag | Cancer treatment using a chimeric receptor antigen (car) against cd19 |
JP6831777B2 (ja) | 2014-07-21 | 2021-02-17 | ノバルティス アーゲー | Cd33キメラ抗原受容体を使用する癌の処置 |
RU2741120C2 (ru) | 2014-07-21 | 2021-01-22 | Новартис Аг | Лечение рака с использованием химерного антигенного рецептора cll-1 |
WO2016014553A1 (fr) | 2014-07-21 | 2016-01-28 | Novartis Ag | Récepteurs d'antigènes chimères synthétisés par l'intermédiaire d'une sortase |
RU2751660C2 (ru) | 2014-07-21 | 2021-07-15 | Новартис Аг | Лечение злокачественного новообразования с использованием гуманизированного химерного антигенного рецептора против всма |
CN107108744B (zh) | 2014-08-19 | 2020-09-25 | 诺华股份有限公司 | 抗cd123嵌合抗原受体(car)用于癌症治疗 |
CA2961636A1 (fr) | 2014-09-17 | 2016-03-24 | Boris ENGELS | Ciblage de cellules cytotoxiques avec des recepteurs chimeriques pour l'immunotherapie adoptive |
CN106973568B (zh) | 2014-10-08 | 2021-07-23 | 诺华股份有限公司 | 预测针对嵌合抗原受体疗法的治疗应答性的生物标志及其用途 |
SG11201705293WA (en) | 2014-12-29 | 2017-07-28 | Novartis Ag | Methods of making chimeric antigen receptor-expressing cells |
WO2016115482A1 (fr) | 2015-01-16 | 2016-07-21 | Novartis Pharma Ag | Promoteurs de phosphoglycérate kinase 1 (pgk) et procédés d'utilisation pour l'expression d'un récepteur antigénique chimérique |
US11161907B2 (en) | 2015-02-02 | 2021-11-02 | Novartis Ag | Car-expressing cells against multiple tumor antigens and uses thereof |
IL303972A (en) | 2015-04-08 | 2023-08-01 | Novartis Ag | CD20 treatments, CD22 treatments and combined treatments with CD19 chimeric antigen receptor expressing cell |
ES2948133T3 (es) | 2015-04-17 | 2023-08-31 | Novartis Ag | Métodos para mejorar la eficacia y expansión de células que expresan un receptor de antígeno quimérico |
JP7146632B2 (ja) | 2015-07-21 | 2022-10-04 | ノバルティス アーゲー | 免疫細胞の有効性および増大を改善する方法 |
WO2017027392A1 (fr) | 2015-08-07 | 2017-02-16 | Novartis Ag | Traitement du cancer à l'aide des protéines de récepteur cd3 chimères |
CN116334205A (zh) | 2015-09-03 | 2023-06-27 | 诺华股份有限公司 | 预测细胞因子释放综合征的生物标志物 |
UA126278C2 (uk) | 2015-09-21 | 2022-09-14 | Аптево Рісьорч Енд Девелопмент Ллс | Поліпептиди, які зв'язують cd3 |
MA44140A (fr) | 2015-12-22 | 2021-05-19 | Dana Farber Cancer Inst Inc | Récepteur d'antigène chimérique (car) contre la mésothéline et anticorps contre l'inhibiteur de pd-l1 pour une utilisation combinée dans une thérapie anticancéreuse |
EP3432924A1 (fr) | 2016-03-23 | 2019-01-30 | Novartis AG | Mini-corps sécrétés par des cellules et leurs usages |
TW202340473A (zh) | 2016-10-07 | 2023-10-16 | 瑞士商諾華公司 | 利用嵌合抗原受體之癌症治療 |
WO2018140725A1 (fr) | 2017-01-26 | 2018-08-02 | Novartis Ag | Compositions de cd28 et procédés pour une thérapie à base de récepteur antigénique chimérique |
CN110582288A (zh) | 2017-02-28 | 2019-12-17 | 恩多塞特公司 | 用于car t细胞疗法的组合物和方法 |
SG11201907434RA (en) | 2017-03-22 | 2019-10-30 | Novartis Ag | Compositions and methods for immunooncology |
US11999802B2 (en) | 2017-10-18 | 2024-06-04 | Novartis Ag | Compositions and methods for selective protein degradation |
BR112020014913A2 (pt) | 2018-01-22 | 2020-12-08 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Métodos para uso de células t car |
CA3100724A1 (fr) | 2018-06-13 | 2019-12-19 | Novartis Ag | Recepteurs antigenes chimeres de la proteine de l'antigene de maturation des lymphocytes b (bcma) et utilisations connexes |
CN110627895B (zh) * | 2018-06-25 | 2021-03-23 | 北京大学 | 肺癌特异性tcr及其分析技术和应用 |
EP3843778A1 (fr) | 2018-08-31 | 2021-07-07 | Invectys Sa | Récepteurs d'antigènes chimériques contre de multiples isoformes de hla-g |
MX2022006365A (es) | 2019-11-26 | 2022-06-22 | Novartis Ag | Receptores de antigeno quimerico cd19 y cd22 y usos de los mismos. |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE260880T1 (de) | 1986-09-11 | 1988-11-03 | Dana-Farber Cancer Institute, Inc., Boston, Mass., Us | Verfahren zur ausloesung der zytotoxizitaet. |
JP3040121B2 (ja) | 1988-01-12 | 2000-05-08 | ジェネンテク,インコーポレイテッド | 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法 |
FI105320B (fi) | 1988-04-04 | 2000-07-31 | Oncogen | Menetelmä vasta-aineheterokonjugaattien valmistamiseksi, joita käytetään imusoluaktiivisuuden säätelyssä ja diagnoosissa |
JP3249516B2 (ja) | 1990-10-31 | 2002-01-21 | ソマティクス セラピー コーポレイション | 遺伝子治療のためのレトロウイルスのベクター |
CA2074825C (fr) * | 1990-12-14 | 2005-04-12 | Daniel J. Capon | Chaines chimeriques pour cheminements de signaux de recepteurs |
US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
AU662311B2 (en) * | 1991-02-05 | 1995-08-31 | Novartis Ag | Recombinant antibodies specific for a growth factor receptor |
FR2672901B1 (fr) | 1991-02-15 | 1994-09-30 | Immunotech Sa | Nouvelles molecules de dna recombinants codant pour une chaine du recepteur pour l'antigene des cellules t, procede de preparation, anticorps et medicaments les renfermant. |
WO1992015326A1 (fr) | 1991-02-27 | 1992-09-17 | The Regents Of The University Of California | Immunogenicite a mediation par complexe de ciblage |
NZ241855A (en) | 1991-03-07 | 1994-04-27 | Gen Hospital Corp | Use of therapeutic cells to obtain cellular response to infection, tumours or autoimmune-generated cells, cells with chimaeric receptors (with binding component and destruction signal), dna encoding the receptor, vectors and antibodies to receptor |
US5939531A (en) | 1991-07-15 | 1999-08-17 | Novartis Corp. | Recombinant antibodies specific for a growth factor receptor |
WO1993019163A1 (fr) * | 1992-03-18 | 1993-09-30 | Yeda Research And Development Co, Ltd. | Genes de recepteurs chimeres et cellules transformees au moyen desdits genes |
JPH07505412A (ja) | 1992-04-14 | 1995-06-15 | ブリティッシュ バイオテック ファーマシューティカルズリミテッド | Ctl応答の誘導 |
NZ285395A (en) | 1994-05-02 | 1998-10-28 | Novartis Ag | Chimeric antibody, cancer treatment |
-
1995
- 1995-04-20 NZ NZ285395A patent/NZ285395A/xx not_active IP Right Cessation
- 1995-04-20 AU AU24469/95A patent/AU694222B2/en not_active Ceased
- 1995-04-20 JP JP52796595A patent/JP3742103B2/ja not_active Expired - Fee Related
- 1995-04-20 DE DE69528894T patent/DE69528894T2/de not_active Expired - Lifetime
- 1995-04-20 DK DK95918576T patent/DK0758394T3/da active
- 1995-04-20 CA CA2188422A patent/CA2188422C/fr not_active Expired - Lifetime
- 1995-04-20 EP EP95918576A patent/EP0758394B1/fr not_active Expired - Lifetime
- 1995-04-20 WO PCT/EP1995/001494 patent/WO1995030014A1/fr active IP Right Grant
- 1995-04-20 ES ES95918576T patent/ES2185705T3/es not_active Expired - Lifetime
- 1995-04-20 PT PT95918576T patent/PT758394E/pt unknown
- 1995-04-20 KR KR1019960706165A patent/KR100373813B1/ko not_active IP Right Cessation
- 1995-04-20 AT AT95918576T patent/ATE228166T1/de active
- 1995-04-24 TW TW084103999A patent/TW428026B/zh active
- 1995-04-28 ZA ZA953440A patent/ZA953440B/xx unknown
- 1995-04-28 IL IL11353095A patent/IL113530A0/xx not_active IP Right Cessation
-
1996
- 1996-10-25 FI FI964311A patent/FI119191B/fi not_active IP Right Cessation
- 1996-11-01 NO NO19964641A patent/NO316923B1/no not_active IP Right Cessation
-
2000
- 2000-06-19 US US09/596,774 patent/US6984382B1/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
JP3742103B2 (ja) | 2006-02-01 |
JPH09512176A (ja) | 1997-12-09 |
US6984382B1 (en) | 2006-01-10 |
FI119191B (fi) | 2008-08-29 |
EP0758394A1 (fr) | 1997-02-19 |
KR100373813B1 (ko) | 2003-10-08 |
ZA953440B (en) | 1995-11-02 |
ATE228166T1 (de) | 2002-12-15 |
IL113530A0 (en) | 1995-07-31 |
CA2188422C (fr) | 2011-03-15 |
NO316923B1 (no) | 2004-06-28 |
FI964311A0 (fi) | 1996-10-25 |
CA2188422A1 (fr) | 1995-11-09 |
AU2446995A (en) | 1995-11-29 |
FI964311A (fi) | 1996-10-25 |
NO964641D0 (no) | 1996-11-01 |
PT758394E (pt) | 2003-04-30 |
ES2185705T3 (es) | 2003-05-01 |
DE69528894D1 (de) | 2003-01-02 |
AU694222B2 (en) | 1998-07-16 |
DE69528894T2 (de) | 2003-03-27 |
NZ285395A (en) | 1998-10-28 |
TW428026B (en) | 2001-04-01 |
NO964641L (no) | 1996-11-01 |
WO1995030014A1 (fr) | 1995-11-09 |
EP0758394B1 (fr) | 2002-11-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK0758394T3 (da) | Bifunktionelt protein, fremstilling og anvendelse | |
NO934801L (no) | CTL4A reseptor, fusjonsproteiner som inneholder den og anvendelse derav | |
IL112390A0 (en) | A cell which expresses chimeric receptors, DNA and vectors encoding said receptors and pharmaceutical compositions containing the same | |
NO963018D0 (no) | CTLA4-mutantmolekyler og anvendelser derav | |
NZ333915A (en) | Soluble monovalent and multivalent MHC class II fusion proteins | |
ES2093623T3 (es) | Receptores monovalentes y oligovalentes, bioespecificos y oligoespecificos, su preparacion y empleo. | |
WO2002077029A3 (fr) | Cellules immunitaires specifiques a cd19 redirigees | |
KR927003847A (ko) | 수용체-결합된 신호 변환 경로를 위한 키메라 사슬 | |
WO1996013593A3 (fr) | Recepteurs de lymphocites t monocatenaires solubles | |
WO1999000010A3 (fr) | Animaux transgeniques exprimant les recepteurs de fc humains | |
DE69435261D1 (de) | Menschlicher rezeptor h4-1bb | |
EP1019439A4 (fr) | Proteines solubles du recepteur des lymphocytes t a chaine unique | |
Sharon et al. | A 100-kilodalton protein is associated with the murine interleukin 2 receptor: biochemical evidence that p100 is distinct from the alpha and beta chains. | |
Eilat et al. | Secretion of a soluble, chimeric gamma delta T-cell receptor-immunoglobulin heterodimer. | |
WO1996021028A3 (fr) | Recepteurs de lymphocytes t heterodimeres solubles et leurs anticorps | |
AU3283693A (en) | Specific antibodies against activated platelets, the preparation thereof and the use thereof in diagnosis and therapy | |
AU2525597A (en) | Monoclonal antibodies binding human growth hormone (hgh) | |
RU94026276A (ru) | Рецепторы интерлейкина-12 и антител | |
AU2002323894A1 (en) | Costimulating t-cell polypeptide, monoclonal antibodies, their preparation and use |